bit.bio Raises in Excess of $100 Million in First Close of Series B Financing
Funding will accelerate clinical development of cell therapies using breakthrough gene engineering technology opti-oxTM Human cell coding company bit.bio today announces the first close of their Series
Source: finanznachrichten.de